Recent advances in the management of castration resistant prostate cancer

BY STYLIANI GERMANOU, SOPHIE MERRICK AND SIMON CHOWDHURY

Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of new metastases. The management of castrate resistant prostate cancer has evolved over the last decade. In 2004, docetaxel became the first treatment to show a survival benefit and emerged as standard of care in CRPC [1]. However new therapeutic options have expanded rapidly since 2011 including second-line chemotherapy, second generation hormonal targeted therapy and bone seeking radionuclides. In addition, bisphosphonates and denosumab have decreased skeletal related adverse events, whilst improving quality of life.

Over the last five years, treating men with CRPC has become more challenging, as there are more available treatment options including clinical trials examining sequencing or combination of treatment. This review will summarise the approved available therapeutic options in patients with metastatic castrate resistant prostate cancer.

Androgen deprivation therapy (ADT)
ADT remains the standard systemic therapy in locally advanced and metastatic prostate cancer. This is for both castration sensitive and resistant disease as the androgen receptor remains functionally active in both disease states. In 1941 Huggins and Hodges first demonstrated regression of prostate carcinoma through endocrine control [2]. ADT decreases circulating testosterone to castrate levels resulting in lower cancer cell proliferation and subsequently induction of apoptosis, but does not typically eradicate the cancer.

There are two forms of medical ADT, luteinising hormone-releasing hormone (LHRH) agonists and antagonists. LHRH analogues stimulate LH receptors in the pituitary gland leading to LH receptor down regulation, resulting in castration in two to four weeks. Testosterone may rise in first two to three weeks, with a risk of tumour flare up, therefore co-treatment with an antiandrogen is started two weeks prior to the initiation of LHRH agonists. Ninety percent of men respond with a median duration of 12-18 months [5]. Equally LHRH antagonists bind to LHRH receptors in the pituitary gland, resulting in rapid and profound testosterone suppression. They are used predominately in patients at risk of spinal cord compression or with a high burden of symptomatic disease.

Chemotherapy
Docetaxel
Docetaxel is a microtubule inhibitor, it is given intravenously every three weeks, up to a maximum of 10 cycles, lasting 30 weeks in metastatic CRPC. It was approved and licensed as first-line therapy for metastatic CRPC in 2004 following the results of the TAX-327 trial [3]. The TAX 327 trial compared docetaxel with mitoxantrone demonstrating a 2.5-month median survival benefit (18.9 vs. 16.4 months). Docetaxel was associated with higher incidence of grade three to four toxicities, however it also showed significant reduction in pain by 35%.

Docetaxel is now being used earlier in patients with hormone sensitive metastatic prostate cancer, based on the results of the CHAARTED and STAMPEDE trials. In 2014 the CHAARTED study reported a survival benefit of 14 months (58 vs. 44 months) when docetaxel was added to ADT in men with metastatic hormone sensitive prostate cancer [4]. In 2015 the STAMPEDE trial showed similar results with an associated survival benefit of 10 months for the addition of docetaxel to ADT in men with both locally advanced and metastatic hormone sensitive prostate cancer (81 vs. 71 months). In the subgroup analysis in metastatic disease the survival benefit was significantly longer at 15 months (45 vs. 60 months) [5]. Given this compelling data, treatment has now changed to incorporate docetaxel.

The common side-effects of docetaxel are peripheral sensory neuropathy, neutropenia, febrile neutropenia, diarrhoea, nausea and fatigue; treatment is generally better tolerated on hormone sensitive setting as patients are fitter. Increased incidence of neutropenia noted in 12% and febrile neutropenia in 15%.

Second generation androgen receptor targeted therapies
Abiraterone
Abiraterone inhibits the androgen synthesis pathway though blockade of 17-a-hydroxylase and lowers the testosterone levels more than ADT alone. It is an oral drug and is given with low dose oral prednisolone to minimise the side-effects of mineralocorticoid excess. The COU-AA-302 trial, which compared abiraterone plus prednisolone against placebo plus prednisolone in men with metastatic CRPC without previous chemotherapy, showed significant longer overall survival benefit of 4.3 months (34.7 vs. 30.3 months) [6]. The COU-AA-301 trial, which compared abiraterone plus prednisolone versus placebo with prednisolone in men with metastatic CRPC with previous chemotherapy, showed overall survival benefit of 4.6 months (15.8 vs. 11.2 months). In the sub-analysis, pain control was significantly better in the abiraterone group (45% vs. 28.8%), with faster time to palliation of pain (5.6 vs. 13.7 months) [7].

Abiraterone is licensed and NICE approved in pre and post docetaxel setting. It is well tolerated with rare side-effects of fatigue, fluid retention, hypertension, cardiac disorders, hypokalaemia and liver dysfunction.

Enzalutamide
Enzalutamide is an oral androgen receptor inhibitor, which inhibits nuclear translocation and impairs the androgen receptor binding to DNA thus preventing gene expression and growth, survival and proliferation of prostate cancer cells. Trials conducted for this second generation anti-androgen agent, all showing superiority to either placebo or bicalutamide, pre
Enzalutamide is approved and NICE approved in the pre and post docetaxel setting. It is well tolerated with most common side-effects of fatigue, hot flushes, diarrhoea, musculoskeletal pain, headache and hypertension. In the AFFIRM study a low incidence of seizures was reported (0.6%).

Other systemic anti-cancer therapies

Cabazitaxel
Cabazitaxel is a second generation taxane, licensed as second-line chemotherapy after docetaxel. The TROPIC trial compared cabazitaxel against mitoxantrone plus prednisolone in men with metastatic CRPC and showed an overall survival benefit of 2.4 months in the cabazitaxel arm (15.1 vs. 12.7 months) [12]. The side-effects were similar to docetaxel but with a higher incidence of neutropenia noted, grade 3-4 in 82% and febrile neutropenia in 8%.

Radium 223
Radium 223 is an alpha-emitting, bone seeking, calcium mimetic that selectively targets and binds to increased areas of bone turnover in bone metastases. The ALSYMPCA trial compared radium 223 against placebo in patients with CRPC and bone metastases. Median overall survival was 3.6 months longer (14.9 vs. 11.3 months) [13]. A significant improvement in median time to first symptomatic skeletal event was also seen in the radium 223 arm (15.6 vs. 9.8 months) and an overall improvement in quality of life. The most common side-effects reported are: diarrhoea, nausea, peripheral oedema and bone marrow suppression.

Radium 223 is licensed and approved by NICE for patients who have previously been treated with docetaxel and available via the Cancer Drugs Fund for patients who are not fit for docetaxel or who have declined chemotherapy. It is licensed only in patients with bone (two or more bones) and non-visceral metastatic disease. Radium 223 is given intravenously once every four weeks for six months in commissioned centres in collaboration with the treating oncologist and nuclear medicine specialists.

Role of biphosphonates and bone targeted therapy

Ninety percent of patients with metastatic CRPC have bone metastases and significant risk of skeletal events. The role of zoledronic acid and denosumab to prevent adverse skeletal events and improve pain and quality of life has proven to be beneficial. Zometa is a bisphosphonate and denosumab, a human monoclonal antibody directed against RANK ligand to inhibit osteoclast mediated bone destruction. A study comparing zometa versus denosumab showed a slightly longer time to skeletal related events with denosumab (20.7 vs. 17.1 months) [14].

Denosumab is administrated as a subcutaneous injection 120mg every four weeks, with a higher risk of hypocalcaemia when compared with zometa, which is administered intravenously every three to four weeks. The latter has a risk of renal impairment and both agents a similar risk of osteonecrosis of the jaw.

Future

Mechanisms of resistance
Recent evidence has suggested drug resistance in patients who do not respond to abiraterone or enzalutamide, may be associated with the androgen receptor variant: AR-V7. A prospective study showed that 39% of patients treated with enzalutamide and 19% with abiraterone had detectable AR-V7 in their circulating tumour cells [15]. Other studies have
showed that patients not responding to abiraterone may have androgen receptor gene aberrations (duplication of a specific nucleotide sequence), however patients with AR-V7 variant may respond better to docetaxel but further studies need to be conducted to determine if treatment decisions based on the molecular profile will improve outcomes. Therefore, when there is no satisfactory PSA response to selected treatment, we need to consider the underlying possibility of resistance and stop treatment earlier.

DNA repair abnormalities

The recent phase two TOPARP looked at the poly-adenosine diphosphate ribose polymerase (PARP) inhibitor, olaparib, in metastatic CRPC. It showed increased activity in men with defects in DNA repair genes who have not responded to previous therapies [16]. The results are exciting as they support personalised treatment and the role of PARPi is being investigated in phase three studies in CRPC.

Immunotherapy / other targeted therapies

Immunotherapy studies have so far failed to show promising survival results. Other targeted therapies such as cabozantinib, a tyrosine kinase inhibitor, have shown promising results in men with CRPC, previously treated with docetaxel in phase two study but this result was not mirrored in a phase three trial.

Combination / sequential treatment

Other studies are examining the combination of different treatments, such as dual AR blockade with enzalutamide and abiraterone. In addition other trials are looking at different sequences of drugs, such as combining enzalutamide with docetaxel [17] early in the treatment pathway.

Conclusion

Important advances have been made in the treatment of CRPC since docetaxel approval in 2004. All these new agents have shown a median survival benefit of two to five months. A systematic approach needs to be followed to personalise treatment based on the burden of the disease, presence of visceral or non-visceral bone metastases, degree and severity of symptoms, performance status and medical comorbidities, previous use of docetaxel chemotherapy and side-effect profile. Molecular profiling will aid the ability to tailor therapy and improve further survival and quality of life. Treatment decision is challenging, therefore patients should be managed in specialist multidisciplinary teams and offered entry into clinical trials that help answer these questions.

References


Declaration of competing interests: None declared.

TAKE HOME MESSAGES

- Androgen deprivation therapy remains the mainstay of systemic treatment for metastatic prostate cancer.
- New therapeutic options have expanded rapidly including second-line chemotherapy, second generation hormonal targeted therapy and bone seeking radionuclides.
- PARP inhibitors have shown initial promise in patients with defects in DNA repair genes.
- Sequential or combination therapy studies aiming to overcome resistance are currently ongoing.

AUTHORS

Styliani Germanou,
Registrar in Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London.

Sophie Merrick,
Clinical Fellow in Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London.

Simon Chowdhury
Consultant Medical Oncologist, Guy’s and St Thomas’ NHS Foundation Trust, London.

E: simon.chowdhury@gstt.nhs.uk

Declanation of competing interests: None declared.